Anthera Pharmaceuticals (Anthera Pharmaceuticals) Total Current Assets : $8.74 Mil (As of Mar. 2018)

View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Anthera Pharmaceuticals's total current assets for the quarter that ended in Mar. 2018 was $8.74 Mil.

Anthera Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Anthera Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Total Current Assets Chart

Anthera Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Current Assets

Get a 7-Day Free Trial

26.30

3.02

47.86

22.71

3.19

Anthera Pharmaceuticals Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Total Current Assets	Get a 7-Day Free Trial															22.87	13.95	7.85	3.19	8.74

Anthera Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Anthera Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.196	+	0	+	0	+	0.995
	=	3.19

Anthera Pharmaceuticals's Total Current Assets for the quarter that ended in Mar. 2018 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.086	+	0	+	0	+	0.653
	=	8.74

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Anthera Pharmaceuticals (OTCPK:ANTH) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Anthera Pharmaceuticals's Liquidation Value for the quarter that ended in Mar. 2018 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.086	-	3.35	+	0.75 * 0	+	0.5 * 0
=	4.74

Anthera Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545

Website

http://www.anthera.com

Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

Executives

Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr	officer: Chief Medical Officer	10301 STELLA LINK HOUSTON TX 77025
Brian Mueller	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson	officer: Chief Technology Officer	25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson	officer: Chief Regulatory Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle	director	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington	officer: Interim Chief Medical Officer	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin	officer: Chief Medical Officer	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe	officer: CFO and Chief Business Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines

From GuruFocus

Major US Indexes End Higher Monday

By Julie Young • 11-08-2021

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-12-2010

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2010

Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets

By Marketwired Marketwired • 06-27-2018